The estimated Net Worth of Frank Ruffo is at least $3.93 Milhão dollars as of 10 March 2022. Mr. Ruffo owns over 12,823 units of Aclaris Therapeutics Inc stock worth over $238,222 and over the last 9 years he sold ACRS stock worth over $2,527,086. In addition, he makes $1,162,880 as Co-Founder e Chief Financial Officer at Aclaris Therapeutics Inc.
Frank has made over 16 trades of the Aclaris Therapeutics Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he sold 12,823 units of ACRS stock worth $199,398 on 10 March 2022.
The largest trade he's ever made was selling 87,339 units of Aclaris Therapeutics Inc stock on 22 April 2021 worth over $2,310,117. On average, Frank trades about 9,933 units every 49 days since 2015. As of 10 March 2022 he still owns at least 201,883 units of Aclaris Therapeutics Inc stock.
You can see the complete history of Mr. Ruffo stock trades at the bottom of the page.
Frank Ruffo serves as Co-Founder, Chief Financial Officer of the Company. From January 2014 to December 2015, Mr. Ruffo served part-time as a financial consultant at Ralexar Therapeutics, Inc., a specialty dermatology company. Mr. Ruffo also served part-time as the Chief Financial Officer of VenatoRx Pharmaceuticals Inc., a pharmaceutical company, from 2011 to 2014 and the Chief Financial Officer of BioLeap, Inc. from 2010 to 2013. Prior to joining our company, Mr. Ruffo co-founded and served as Chief Financial Officer of Vicept Therapeutics, Inc. from 2009 until its acquisition by Allergan, Inc. in July 2011. Prior to joining Vicept Therapeutics, Inc., from 1996 to 2008, Mr. Ruffo served as the Vice President, Finance and Controller of CollaGenex Pharmaceuticals, Inc. He is a certified public accountant in Pennsylvania (inactive since 2008). Mr. Ruffo received his B.S. degree in business administration with a major in accounting from LaSalle University.
As the Co-Founder e Chief Financial Officer of Aclaris Therapeutics Inc, the total compensation of Frank Ruffo at Aclaris Therapeutics Inc is $1,162,880. There are 3 executives at Aclaris Therapeutics Inc getting paid more, with Neal Walker having the highest compensation of $3,150,020.
Frank Ruffo is 54, he's been the Co-Founder e Chief Financial Officer of Aclaris Therapeutics Inc since 2016. There are 6 older and 6 younger executives at Aclaris Therapeutics Inc. The oldest executive at Aclaris Therapeutics Inc is Maxine Gowen, 62, who is the Independent Director.
Frank's mailing address filed with the SEC is C/O ACLARIS THERAPEUTICS, INC., 640 LEE ROAD, SUITE 200, WAYNE, PA, 19087.
Over the last 9 years, insiders at Aclaris Therapeutics Inc have traded over $101,608,525 worth of Aclaris Therapeutics Inc stock and bought 10,163,038 units worth $66,383,599 . The most active insiders traders include Braden Michael Leonard, Capital Management, Llc Kol..., eLlc Fmr. On average, Aclaris Therapeutics Inc executives and independent directors trade stock every 17 days with the average trade being worth of $111,818. The most recent stock trade was executed by Kevin Balthaser on 1 September 2024, trading 1,000 units of ACRS stock currently worth $1,180.
aclaris therapeutics, inc. is a dermatologist-led biopharmaceutical company committed to identifying, developing and commercializing innovative therapies to address significant unmet needs in dermatology, both medical and aesthetic, and immunology. aclaris is focused on market segments with no fda-approved medications or where treatment gaps exist. aclaris was founded by dermatologists and is led by a team with extensive experience in developing and commercializing dermatologic treatments.
Aclaris Therapeutics Inc executives and other stock owners filed with the SEC include: